Back to Search Start Over

Researching COVID to enhance recovery (RECOVER) pregnancy study: Rationale, objectives and design

Authors :
Torri D. Metz
Rebecca G. Clifton
Richard Gallagher
Rachel S. Gross
Leora I. Horwitz
Vanessa L. Jacoby
Susanne P. Martin-Herz
Myriam Peralta-Carcelen
Harrison T. Reeder
Carmen J. Beamon
Marie-Abele Bind
James Chan
A. Ann Chang
Lori B. Chibnik
Maged M. Costantine
Megan L. Fitzgerald
Andrea S. Foulkes
Kelly S. Gibson
Nick Güthe
Mounira Habli
David N. Hackney
Matthew K. Hoffman
M. Camille Hoffman
Brenna L. Hughes
Stuart D. Katz
Victoria Laleau
Gail Mallett
Hector Mendez- Figueroa
Vanessa Monzon
Anna Palatnik
Kristy T.S. Palomares
Samuel Parry
Christian M. Pettker
Beth A. Plunkett
Athena Poppas
Uma M. Reddy
Dwight J. Rouse
George R. Saade
Grecio J. Sandoval
Shannon M. Schlater
Frank C. Sciurba
Hyagriv N. Simhan
Daniel W. Skupski
Amber Sowles
Tanayott Thaweethai
Gelise L. Thomas
John M. Thorp
Alan T. Tita
Steven J. Weiner
Samantha Weigand
Lynn M. Yee
Valerie J. Flaherman
Publication Year :
2023
Publisher :
Cold Spring Harbor Laboratory, 2023.

Abstract

ImportancePregnancy induces unique physiologic changes to the immune response and hormonal changes leading to plausible differences in the risk of developing post-acute sequelae of SARS-CoV-2 (PASC), or Long COVID. Exposure to SARS-CoV-2 during pregnancy may also have long-term ramifications for exposed offspring, and it is critical to evaluate the health outcomes of exposed children. The National Institutes of Health (NIH) Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC aims to evaluate the long-term sequelae of SARS-CoV-2 infection in various populations. RECOVER- Pregnancy was designed specifically to address long-term outcomes in maternal-child dyads.MethodsRECOVER-Pregnancy cohort is a combined prospective and retrospective cohort that proposes to enroll 2,300 individuals with a pregnancy during the COVID-19 pandemic and their offspring exposed and unexposed in utero, including single and multiple gestations. Enrollment will occur both in person at 27 sites through theEunice Kennedy ShriverNational Institutes of Health Maternal-Fetal Medicine Units Network and remotely through national recruitment by the study team at the University of California San Francisco (UCSF). Adults with and without SARS-CoV-2 infection during pregnancy are eligible for enrollment in the pregnancy cohort and will follow the protocol for RECOVER-Adult including validated screening tools, laboratory analyses and symptom questionnaires followed by more in-depth phenotyping of PASC on a subset of the overall cohort. Offspring exposed and unexposed in utero to SARS-CoV-2 maternal infection will undergo screening tests for neurodevelopment and other health outcomes at 12, 18, 24, 36 and 48 months of age. Blood specimens will be collected at 24 months of age for SARS-CoV-2 antibody testing, storage and anticipated later analyses proposed by RECOVER and other investigators.DiscussionRECOVER-Pregnancy will address whether having SARS-CoV-2 during pregnancy modifies the risk factors, prevalence, and phenotype of PASC. The pregnancy cohort will also establish whether there are increased risks of adverse long-term outcomes among children exposed in utero.RegistrationNCT05172024

Details

Database :
OpenAIRE
Accession number :
edsair.doi...........8ebd7ef4e34c1faed1a599a056e969c2